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Brucella abortus rough lipopolysaccharide (LPS) mutants were obtained by transposon insertion into two wbk
genes (wbkA [putative glycosyltransferase; formerly rfbU] and per [perosamine synthetase]), into manB (pmm
[phosphomannomutase; formerly rfbK]), and into an unassigned gene. Consistent with gene-predicted roles,
electrophoretic analysis, 2-keto-3-manno-D-octulosonate measurements, and immunoblots with monoclonal
antibodies to O-polysaccharide, outer and inner core epitopes showed no O-polysaccharide expression and no
LPS core defects in the wbk mutants. The rough LPS of manB mutant lacked the outer core epitope and the
gene was designated manBcore to distinguish it from the wbk manBO-Ag. The fourth gene (provisionally desig-
nated wa**) coded for a putative glycosyltransferase involved in inner core synthesis, but the mutant kept the
outer core epitope. Differences in phage and polymyxin sensitivity, exposure or expression of outer membrane
protein, core and lipid A epitopes, and lipid A acylation demonstrated that small changes in LPS core caused
significant differences in B. abortus outer membrane topology. In mice, the mutants showed different degrees
of attenuation and induced antibodies to rough LPS and outer membrane proteins. Core-defective mutants and
strain RB51 were ineffective vaccines against B. abortus in mice. The mutants per and wbkA induced protection
but less than the standard smooth vaccine S19, and controls suggested that anti O-polysaccharide antibodies
accounted largely for the difference. Whereas no core-defective mutant was effective against B. ovis, S19, RB51,
and the wbkA and per mutants afforded similar levels of protection. These results suggest that rough Brucella
vaccines should carry a complete core for maximal effectiveness.
Brucellosis is a zoonotic disease that causes heavy economic
losses and human suffering. Under most conditions, vaccina-
tion and serological identification and culling of infected ani-
mals are the only practical means to achieve its eradication, but
the best vaccines available (Brucella abortus S19 for cattle and
B. melitensis Rev1 for sheep and goats) may induce abortions
when used in pregnant animals and are virulent for humans.
Moreover, like field strains, they carry a cell surface smooth-
type lipopolysaccharide (S-LPS) whose immunodominant sec-
tion (the N-formylperosamine O-polysaccharide) induces an
antibody response that may be difficult to distinguish from that
resulting from a true infection (25, 48). This complicates sero-
diagnosis because the tests currently used detect antibodies to
the O-polysaccharide.
To overcome these problems, several strategies are possible.
The early observation that rough (R) B. abortus strains are
attenuated and do not agglutinate with antibody elicited by S
bacteria (63) soon led to the concept of Brucella R vaccines
and, more than 50 years ago, the spontaneous R mutant B.
abortus 45/20 was studied for this purpose. However, strain
45/20 was unstable, and its use was abandoned (1, 48). The
same strategy was followed to develop B. abortus RB51, a
spontaneous mutant selected after repeated in vitro passage of
B. abortus 2308 in the presence of rifampin and penicillin (61).
Consequently, RB51 is resistant to rifampin (61), the antibiotic
of choice in the treatment of brucellosis in pregnant women,
children, and Brucella endocarditis cases (5). It has been
pointed out that Brucella strains carrying precise LPS muta-
tions should be advantageous over empirically selected R mu-
tants (1) and, in fact, B. melitensis VTRM1 and B. suis VTRS1
wboA (former rfbU) mutants afford better protection than
RB51 against homologous and heterologous Brucella spp. in
mice (73).
One problem inherent to Brucella R vaccines is that they
may be overattenuated and may thus fail to elicit protective
immunity. This is so because the S-LPS is a key virulence factor
of Brucella (47). The role of the O-polysaccharide in virulence
has been known for a long time and repeatedly confirmed by
using genetically defined R mutants (2, 20, 28, 69, 73), and
there is indirect evidence suggesting that the core is also in-
volved. Although comparisons are not necessarily meaningful
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because of species differences in virulence and aspects of
pathogenesis (63), B. melitensis per mutants (affected only in
the synthesis of N-formylperosamine) multiply in cultured
cells, whereas B. abortus or B. suis manB (pmm; formerly rfbK)
mutants do not (2, 20, 28). Also, Allen et al. (2) found a manB
(rfbK) R mutant to be more attenuated than other R mutants
in mice. However, it remains to be studied whether core dif-
ferences result in a different immunizing capacity, or whether
there are pleiotropic effects on outer membrane (OM) topol-
ogy.
To answer these questions, we selected a series of B. abortus
R mutants differing in polymyxin B sensitivity under the as-
sumption (44, 71) that they should show different degrees of
LPS defects. These mutants were characterized, and we de-
scribe here a new gene involved in B. abortus LPS synthesis.
We also describe the changes in LPS core epitopic structure
and OM topology caused by the mutations and present an
analysis of their attenuation and value as vaccines in mice.
MATERIALS AND METHODS
Bacterial strains and culture conditions. B. abortus2308 (S, virulent) and B.
ovis PA (R, virulent) are challenge strains used in Brucella vaccine studies (38,
73), and B. abortus S19 is the standard S vaccine used in cattle (48). B. abortus
strain 2308 Nalr is a spontaneous nalidixic acid-resistant mutant derived from
strain 2308 (59) and B. abortus RB51 is a live R commercial vaccine. B. melitensis
16M is the reference strain of biotype 1 (3). B. abortus and B. melitensis were
routinely grown on tryptic soy agar or broth or, for infection and immunization
studies, on blood agar base (BAB [no. 2]; Difco Laboratories, Detroit, Mich.) for
48 h at 37°C. B. ovis PA was cultured on the same medium supplemented with
5% of sterile calf serum under a 10% CO2 atmosphere. Mutant strains were
grown in the presence of nalidixic acid (25 g/ml) and kanamycin (50 g/ml).
Transposon mutagenesis and selection of R mutants. Mini-Tn5 mutagenesis
was performed by mating B. abortus 2308 Nalr with Escherichia coli SM10(pir)
harboring the suicidal plasmid pUT/Km, and polymyxin B-sensitive mutants were
selected by screening for viability loss after a short exposure to this antibiotic
(62). Bacteria showing an R phenotype were identified by a negative result in the
coagglutination test with staphylococci coated with immunoglobulin G (IgG) to
the S-LPS (62).
DNA sequencing and sequence analysis. DNA flanking the mini-Tn5 insertion
was cloned and sequenced as described previously (62). Searches for DNA and
protein homologies were performed with the EMBL-European Bioinformatics
Institute server (http://www.ebi.ac.UK/ebihome.html). In addition, sequence
data were obtained from The Institute for Genomic Research website at http:
//www.tigr.org.
Nucleotide sequence accession number. The DNA sequence of the wa** gene
of B. abortus 2308 has been submitted to the GenBank (accession no. AJ427447).
Sensitivity to polymyxin B and brucellaphages. The MIC of polymyxin B was
determined by standard procedures. Sensitivity to S (Tb, Wb, Iz) and R (R/C)-
specific brucellaphages was measured by testing the lysis of bacteria exposed to
serial 10-fold dilutions made from a routine test dilution phage stock (3).
Extraction and purification of Brucella polysaccharides. The protocols used to
prepare the S-LPS hydrolytic polysaccharides (PS) of B. abortus S19 and the
native hapten polysaccharides (NH) of B. melitensis 16M were as described in a
previous work (4). Although both are perosamine O-polysaccharides, NHs differ
from PSs in that the sugar amino groups are only partially formylated and in the
absence of core sugars (4; M. Staaf, G. Widmalm, A. Weintraub, A. Cloeckaert,
A. P. Teixeira-Gomes, R. Díaz, E. Moreno, and I. Moriyo´n, unpublished results).
LPS extraction. (i) Whole-cell LPS. Bacteria (0.5 g) were thoroughly resus-
pended in 2% sodium dodecyl sulfate (SDS)–60 mM Tris-HCl (pH 6.8; 10 ml),
extracted, and digested with proteinase K (1.5 mg), DNase (30 g), and RNase
(30 g); the LPS was then precipitated with isopropanol (26). The precipitate
was analyzed directly by SDS-polyacrylamide gel electrophoresis (PAGE).
(ii) Extraction of S- and R-LPS with organic solvents. B. abortus 2308 Nalr
S-LPSs were obtained by methanol precipitation of the phenol phase of a water-
phenol extract and purified by digestion with nucleases and proteinase K (4).
Free lipids were then removed by a fourfold extraction with chloroform-metha-
nol (2:1 [vol/vol]). To extract the LPS from R mutants, bacteria were first
disintegrated in the presence of nucleases in a 40K French press (SLM Instru-
ments, Inc., Urbana, Ill.) operating at 140 kg/cm2, and the soluble and cell
envelope fractions were separated by ultracentrifugation. The cell envelope was
freeze-dried and extracted either with phenol-water (see above) or by the phe-
nol-chloroform-light petroleum (2:5:8) method at a ratio of 165 mg/ml (23). The
protein content of these preparations, estimated by the modified Lowry method
(43) with bovine serum albumin as a standard, was 6%.
LPS characterization. (i) SDS-PAGE. LPSs were analyzed in either 7- or
17-cm 15% polyacrylamide gels (at a 37.5:1 acrylamide/methylene-bisacrylamide
ratio) in Tris-HCl-glycine and stained by the periodate-alkaline silver method
(68). The R-LPSs of Salmonella enterica serovar Minnesota Ra and Rd mutants
were used as standards.
(ii) Western blots. For Western blots, 17-cm gels were electrotransferred onto
nitrocellulose sheets (Schleicher & Schuell GmbH, Dassel, Germany), blocked
with 3% skim milk in 10 mM phosphate-buffered saline (PBS) with 0.05% Tween
20 overnight, and washed with PBS–0.05% Tween 20. Immune sera were diluted
in this same buffer; after incubation for 3 h at room temperature, the membranes
were washed again, and bound immunoglobulins were detected with peroxidase-
conjugated goat anti-rabbit immunoglobulins (Nordic) and 4-chloro-1-naphthol-
H2O2 (34). Immune sera to R mutants were obtained after two intravenous
injections with 109 viable bacteria at 9-day intervals, followed by two intramus-
cular injections of killed bacteria 3 and 4 months later. A polyclonal serum
specific for the O-polysaccharide was prepared by repeated absorption of the
serum of a B. melitensis 16M-infected rabbit with whole cells of the B. abortus per
mutant, and O specificity was demonstrated by the lack of reactivity with the
R-LPS of the mutant and the positive reactivity with B. abortus PS in an indirect
enzyme-linked immunosorbent assay (ELISA) (see below).
(iii) Dot blots. The reactivity of monoclonal antibodies (MAbs) to OM mol-
ecules was assayed by this method because the variable adherence of the mutants
and wild-type bacteria to polystyrene prevented the use of the ELISA. Expo-
nentially growing bacteria were resuspended in 0.5% phenol, inactivated by
overnight incubation at 37°C, and adjusted to an optical density at 400 nm of 1.0.
Then, 5 l was dispensed onto nitrocellulose membranes (Schleicher & Schuell),
which were incubated overnight in a humid atmosphere and washed three times
with PBS–0.05% Tween (amido black staining showed no quantitative differ-
ences in the adsorption of the mutants to the nitrocellulose). Membranes were
blocked (see above), incubated with the R-LPS-specific MAbs (see below) for
3.5 h at 37°C, and washed with PBS–0.05% Tween, and immunoglobulins were
detected with peroxidase-conjugated goat anti-mouse immunoglobulins (Nordic)
and 4-chloro-1-naphthol-H2O2 as the substrate (34). The intensity of the reaction
was assessed by using the Imagemaster system (Pharmacia Biotech, Uppsala,
Sweden) and is expressed as the optical density per square millimeter. MAbs
Baro-1 and Baro-2 show overlapping reactivities with the outer and inner core
epitopes of Brucella LPS, respectively, and MAb Bala-1 is specific for the dia-
minoglucose disaccharide of the lipid A backbone of Brucella LPS (58). MAb
Bru38 is specific for the C-epitope of the Brucella S-LPS O-polysaccharide (60).
(iv) Kdo. 3-Deoxy-D-manno-2-octulosonic acid (Kdo) was determined colori-
metrically by the thiobarbituric acid method by using pure Kdo and deoxyribose
as the standards with the modifications described previously (4).
(v) Lipid A analysis. Purified LPS was resuspended in 10 mM sodium acetate
(pH 4.5)–1% SDS, hydrolyzed for 1 h at 100°C, and freeze-dried. To remove
SDS, the product was washed six times with ethanol, two times with ethanol
acidified with traces of HCl, and then freeze-dried (31). To determine the degree
of lipid A acylation, samples were dissolved in chloroform-methanol-ammonium-
water (25:14:1:2) and chromatographed on high-performance thin-layer chroma-
tography (HPTLC) silica gel plates (E. Merck, Darmstadt, Germany) by using
the same solvent mixture. Plates were soaked in ethanol-sulfuric acid (1:1), but
instead of charring the image that developed immediately after soaking was
captured with a video camera on a dark background and then inverted and
contrasted by using standard software. The lipid A of Escherichia coli ATCC
35218 (composed mostly of hexa-acylated forms, with minor amounts of penta-
and tetra-acylated forms) was used as a standard.
Accessibility of OM protein (Omp) to antibodies. Omp exposure and/or ex-
pression on the cell surface was assessed by dot blot (see above) with MAbs
A68/07G11/C10 (Omp10), A68/08C03/G03 (Omp16), A76/05C10/A08 (Omp19),
A63/03H02/B01 (Omp2b), and A53/10B02/A01 (Omp1 [Omp89]). In addition,
the following MAbs to Omp3a (formerly Omp25 [32]) were used: A59/05F01/
C09, recognizing an exposed linear epitope (epitope A) corresponding to amino
acids 1 to 15 of the mature protein; A59/10F09/G10, recognizing an internal
linear epitope (epitope B) corresponding to amino acids 166 to 189; and A70/
06B05/A07, A76/02C12/C11, A68/04B10/F05, A68/07D11/B03, and A68/28G06/
C07, all recognizing conformational epitopes (M. Ruiz, J. I. Riezu-Boj, A. Sola-
Landa, A. Cloeckaert, I. Lopez-Gon˜i, F. Borra´s, and I. Moriyo´n, unpublished
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results). Other characteristics of the MAbs have been described previously (8,
13).
Agar gel immunodiffusion. The presence of N-formyl-perosamine polysaccha-
rides was tested by the immunodiffusion method with 1% Noble agar (Difco
Laboratories, Detroit, Mich.) in 10% NaCl–0.1 M KCl–H3BO4 (pH 8.3). The
central well was filled with 20 l of a pool of sera from B. abortus-infected cattle,
and the extracts were dispensed in antigen wells set 4 mm apart. The assay
detected PS and pure NH at concentrations as low as 50 and 5 g/ml, respectively
(4).
Splenic growth curves and residual virulence in mice. Six-week-old female
BALB/c mice (Charles River, Elbeuf, France) were kept in cages with water and
food ad libitum and accommodated under biosafety containment conditions 2
weeks before the experiments were begun. Inocula were prepared in sterile 10
mM PBS (pH 6.85), and 0.1 ml administered to each mouse. Exact doses were
assessed retrospectively by plating serial 10-fold dilutions of the inoculum (30).
For each strain, 30 mice were inoculated intraperitoneally with ca. 108 CFU, and
lots of five animals were anaesthetized, bled, and euthanized 2, 5, 8, 16, 21, and
35 days after inoculation. Spleens were removed aseptically, homogenized indi-
vidually, and diluted in the above-described PBS, and 0.1 ml of each dilution was
seeded in triplicate onto BAB plates (this method allowed the detection of at
least 10 CFU/spleen). Plates were incubated at 37°C for 4 to 5 days in a 10% CO2
atmosphere to determine the CFU/spleen, the data were normalized by loga-
rithmic transformation, and the mean log CFU values  the standard deviations
(SDs; n  5) were calculated. Statistical comparisons were performed by the
one-tailed Student t test, with a previous Fisher F test correction. Residual
virulence was assessed as the 50% recovery time (RT50). For this, animals from
which at least 1 CFU was isolated were considered as infected, and RT50 values
were calculated by using the PROBIT procedure of the SAS statistical package.
Differences were analyzed by regression line comparison by using the same
statistical package (30).
In vivo stability. This was assessed by duplicate plating of the appropriate
splenic dilutions on both BAB and BAB-kanamycin. The phenotypic character-
istics and the presence of the Tn5 were confirmed as described above.
Protection studies. Animal housing and handling and inoculum preparation
were performed as described above. Two groups of immunizations were used.
(i) Live vaccines. Groups of 10 mice each were inoculated intraperitoneally
with 108 CFU of each transposon R mutant and B. abortus RB51/mouse or
subcutaneously with 105 CFU of B. abortus S19/mouse, and unvaccinated con-
trols received sterile buffer intraperitoneally. Four weeks after vaccination, each
group was split, and each half (n 5) was challenged by intraperitoneal injection
of either 5  104 CFU of B. abortus 2308 or 8  104 CFU of B. ovis PA/mouse.
Mice were euthanized by cervical dislocation 2 weeks later, and the CFU of the
challenge strain in the spleens were determined. The vaccine doses, routes, and
challenge intervals were chosen on the basis of previous evidence showing that
they are optimal for this kind of brucellosis study in mice (30, 38, 61, 64), as well
as in preliminary experiments with the R mutants described here. When these
transposon R mutants were used as vaccines, counts were made on BAB (for B.
abortus-challenged mice) or BAB plus serum (for B. ovis-challenged mice) and
on the same media supplemented with kanamycin, and the CFU of the challenge
strain was determined by subtracting the counts on both media. A similar pro-
cedure was used when RB51 or S19 were tested, but the vaccine strains were
differentiated by using rifampin or erythritol instead or kanamycin (RB51 is
rifampin resistant, and S19 is erythritol sensitive). Differentiation of R mutants
and RB51 from B. ovis PA and B. abortus 2308 was confirmed by flooding the
plates with the cytochrome-oxidase reagent or crystal violet-ammonium oxalate,
respectively (3). The mean log CFU  the SD (n  6) per spleen was calculated
for each challenge strain, and statistical comparisons were performed by using
the Fisher protected least-significant-difference test.
(ii) PS and S-LPS. Groups of five mice each were vaccinated subcutaneously
with either PS or a crude S-LPS fraction (100 g/mouse). Controls received 105
CFU/mouse of B. abortus S19 or buffer alone subcutaneously. Eight weeks later,
each mouse was challenged with 5  104 CFU of B. abortus 2308 intraperitone-
ally, and then the CFU in the spleen was determined and statistical analyses were
performed as described for the live vaccines. Doses and time intervals were
chosen on the basis of previous experiments with subcellular brucellosis vaccines
in mice (7, 53).
Antibody response to OM components. The IgG response was measured in an
ELISA with standard 96-well polystyrene plates (Maxisorp; Nunc A/S, Roskilde,
Denmark) coated with either (i) NH or PS at 2.5 g/ml in PBS at 4°C overnight,
(ii) a hot-saline extract (rich in R-LPS and immunodominant Omps of group 3)
(56) at 2.5 g/ml under the same conditions, or (iii) R-LPS from the per mutant
(see Results) at 10 g/ml in 60 mM carbonate buffer (pH 9.6) at 37°C overnight.
Antigen concentrations were determined previously by titration against a panel
of sera from mice infected with B. abortus 2308 or B. ovis PA or from Brucella-
free mice. Nonadsorbed material was removed with four washings of PBS–0.05%
Tween; 100-l aliquots of serial dilutions of pooled sera from each lot of mice
(see above) were dispensed, and then the plates were incubated for 1 h at 37°C.
After an extensive washing with PBS–0.05% Tween, 100 l of a rabbit anti-
mouse IgG-peroxidase conjugate (Pierce Chemical Co., Rockford, Ill.) at 1:1,000
in PBS–0.05% Tween was added to each well, and then incubation continued for
1 h at 37°C. The plates were washed and developed with 100 l of 0.1% ABTS
[diammonium 2,2azinobis(3-ethylbenzthiazolinesulfonate)] (Sigma Chemical
Co., St. Louis, Mo.) plus 0.004% H2O2/well in 0.05 M citrate (pH 4) for 15 min
at 20°C. Optical density readings were made at 405 nm. Reference pools of sera
from Brucella-free mice and B. abortus 2308- and B. ovis PA-infected mice were
included in each plate as controls. For each pool of sera, the results were
expressed as the absorbance of the dilution yielding the maximal differences
between the B. abortus 2308-infected and the Brucella-free mice (1/100 for PS
and 1/50 for other antigens).
RESULTS
Selection of R mutants and genetic characterization. We
have described previously the isolation of polymyxin B-sensi-
tive mutants by transposon mutagenesis of B. abortus 2308 and
screening for viability loss after a controlled exposure to an
excess of this antibiotic (62). Since the O-polysaccharide plays
a role in protection against polymyxin B, these mutants were
further screened for O-polysaccharide defects by a coaggluti-
nation with anti-S-LPS antibodies. Four mutants negative in
this test (designated 9.49, 2.17, 80.16, and 55.30) were then
chosen on the basis of their different polymyxin B sensitivities
(Fig. 1, left panel). All were similarly positive in the acriflavin
agglutination and crystal violet tests.
Southern blots of EcoRI chromosomal DNA digests probed
with a labeled internal fragment of the mini-Tn5 demonstrated
a single insertion in the genome of each mutant (data not
shown). EcoRI fragments containing the mini-Tn5 were
cloned, and sequences flanking the insertion were obtained
with primers complementary to the ends of one of the mini-
Tn5 ends and the cloning vector. Computer database analysis
revealed that the mini-Tn5 was inserted in (i) the 21st nucle-
otide of the perosamine synthetase (per) gene (27, 28) of mu-
tant 9.49, (ii) approximately nucleotide 388 of wbkA (a putative
mannosyltransferase gene) (27) of mutant 2.17, (iii) approxi-
mately nucleotide 824 of a gene putatively coding for a phos-
phomannomutase (manB) (2) of mutant 55.30, and (iv) the
1,631st nucleotide of a 2,166-nucleotide open reading frame
(ORF; provisionally named wa** [see below]) of mutant 80.16.
This gene product was a membrane protein of the glycosyl-
transferase family 25 involved in LPS biosynthesis (10, 15), but
it was different from other putative glycosyltransferases de-
scribed before as involved in LPS synthesis in Brucella (27, 45).
As expected, a search in the complete genome sequence of B.
melitensis 16M and B. suis 1330 (17, 50) revealed single ho-
mologous genes for per (BMEI 1414, BR0521) and wbkA
(BMEI 1404, BR0529), both located in the wbk region (Fig. 2).
The gene homologous to wa** was also in chromosome I,
although in a different region (BMEI 1326, BR0615) (Fig. 2).
On the other hand, the B. melitensis and B. suis manB homo-
logues were in chromosome II (BMEII 0899 and BRA0348),
along with a manC gene putatively coding for both mannose-
6-P-isomerase and mannose-1-P-guanylyltransferase activities
(BMEII 0900, BRA0347) (Fig. 2). Since phenotypic analysis
(see below) revealed a severe core defect, the gene was desig-
nated manBcore (55).
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Surface characterization. In contrast to the parental strain,
per, wbkA, wa**, and manBcore mutants were resistant to the
S-Brucella-specific phages Wb (Fig. 1, central panel), Tb, and
Iz (data not shown) and sensitive to the R-Brucella-specific
phage R/C (Fig. 1, central panel). Moreover, it was observed
that the manBcore mutant showed the lowest R/C phage sensi-
tivity and the highest polymyxin B resistance and that, con-
versely, the wa** mutant had the highest R/C phage sensitivity
and the lowest polymyxin B resistance (Fig. 1).
When probed with anti-O-polysaccharide antibodies, the
four mutants failed to react significantly with either the anti-C
Bru38 MAb (Fig. 1, right panel) or the polyclonal serum (not
shown). Differences in LPS core epitopic structure and/or ex-
posure were suggested by the analyses performed with MAbs
Baro-1 (outer core epitope) and Baro-2 (inner core epitope):
compared to mutants per and wbkA, the wa** mutant showed
decreased reactivity with Baro-2, and the manBcore mutant
showed increased reactivity with both Baro-1 and Baro-2 (Fig.
1, right panel). Exposure of LPS epitopes not directly affected
by the mutations was also tested. The MAb specific for the
lipid A disaccharide did not bind to the surface of the parental
2308 Nalr strain while showing binding to the surface of the R
mutants. In addition, it was observed that the binding of this
MAb to mutant manBcore was more intense than to the other
R mutants (Fig. 1, right panel). As expected, the absence of the
O-polysaccharide also correlated with an increased exposure of
all major Omps. However, not all mutants and Omps were
equivalent in this regard: the manBcore mutant showed the
highest reactivity with MAbs to Omp3a conformational surface
epitopes and also with MAbs to Omp1 and Omp2 (Fig. 3).
Mutants in per and wbkA showed almost identical levels of
reactivity when tested with this same set of MAbs, and inter-
mediate reactivities were observed for mutant wa** with the
anti-Omp3a MAbs (Fig. 3). The same picture was obtained
with MAb A59/05F01/C09 (specific for the linear epitope lo-
cated between amino acids 1 to 15), but MAb A59/10F09/G10
(linear epitope corresponding to amino acids 166 to 189) failed
to react with either the parental strain or the mutants (not
shown). The picture obtained for the lipoproteins was more
complex: whereas the reactivity of the MAb to Omp16 in-
FIG. 1. Surface properties of B. abortus 2308 Nalr and derived R mutants in the genes per, wbkA, wa**, and manBcore (mutants 9.49, 2.17, 80.16,
and 55.30, respectively) probed with polymyxin B, phages R/C and Wb (specific for R and S brucellae, respectively), and anti-LPS MAbs of the
indicated specificities.
FIG. 2. Physical map of the B. melitensis 16M genome regions (A to C) in which the genes homologous to B. abortus per, wbkA, wa**, and
manBcore are located. The map is based on the complete genome sequence of B. melitensis 16M (GenBank accession numbers AE008917 and
AE008918). Open arrows represent ORFs related to LPS biosynthesis (the names of the genes involved are shown). Solid triangles indicate the
sites of the mini-Tn5 insertions in B. abortus mutants.
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creased in the order per 	 wbkA 	 wa** 	 manBcore, almost
converse results were obtained with the anti-Omp19 MAb
(Fig. 3).
To study whether the mutants synthesized N-formyl-pero-
samine polysaccharides remaining within the cell either free or
linked to a cytoplasmic membrane lipid, the following analysis
was conducted. First, 10-mg portions of cell envelopes of each
strain were extracted with phenol-water, and the methanolic
precipitate of the phenol phase was resuspended in 60 l of
water. Then, 10 l of the concentrate was examined by gel
immunoprecipitation, with negative results indicating less than
0.03 (with PS as the standard) or 0.003% (with NH as the
standard) N-formyl-perosamine polysaccharide content. Sec-
ond, proteins in the cytoplasmic fraction (500 mg in 20 ml of
water) were heat denatured and removed by centrifugation,
and the soluble fraction containing the N-formyl-perosamine
polysaccharides (4) was filtered and freeze-dried (40% yield).
This fraction was analyzed directly by gel immunoprecipitation
with negative results at 10 mg/ml, indicating a 0.5% (with PS
as the standard) or 0.05% (with NH as the standard) N-
formyl-perosamine polysaccharide content.
LPS characterization. R-LPSs but no traces of S-LPS were
observed in the SDS-proteinase K extracts (not shown). This
result granted that the phenol-chloroform-light petroleum
method would extract the total cell LPS and, in fact, the R-
LPSs extracted in this way had the same electrophoretic pat-
tern as the SDS-proteinase K R-LPSs. The Kdo contents were
as follows: mutant per, 2.6%; mutant wbkA, 2.9%; mutant
wa**, 4.6%; and mutant manBcore, 7.4% (the percent Kdo
value of the S-LPS of strain 2308 Nalr was 1.0). SDS-PAGE
resolved the R-LPS of the per, wbkA, and wa** mutants into a
major component of mobility similar to that of the serovar
Minnesota Ra LPS, plus a minor component of higher molec-
ular weight that, however, did not overlap with the S-LPS of B.
abortus 2308 Nalr (Fig. 4A) and was not recognized by the
antiserum to the O-polysaccharide in Western blots (Fig. 4B).
This second component was absent from the R-LPS of mutant
manBcore, which contained a third component of mobility
closer to that of the serovar Minnesota Rd LPS (Fig. 4A).
Probing the blots with the appropriate polyclonal antisera con-
firmed the absence of O-chain in the LPSs of the mutants (Fig.
4B) and showed the reactivity of the high- and medium-mo-
lecular-weight components of the LPSs of the per, wbkA, and
wa** mutants with the sera to per mutant (Fig. 4C). These
analyses also demonstrated the immunogenicity of the fastest-
moving component in the R-LPS of mutant manBcore, which
was recognized only by the homologous antiserum (Fig. 4D).
Moreover, as judged by the reactivity with MAbs Baro-1 (outer
core) and Baro-2 (inner core), the manBcore mutant carried the
deficiency in the outer core (Fig. 4E), and the wa** mutant
carried the deficiency in the inner core (Fig. 4F).
Changes in the pattern of lipid A acylation were also exam-
ined. Two lipid A forms (Fig. 5, bands c and d) of lower relative
mobility than the two dominant forms (Fig. 5, bands a and b)
of the parental strain S-LPS were clearly observed in all R-
LPSs. Comparison with the standard (lane Ec) showed that the
FIG. 3. Exposure of the major Omps on the surface of B. abortus 2308 Nalr and derived R mutants assessed as the reactivity of whole cells with
specific MAbs.
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lower relative mobility bands corresponded to underacylated
lipid A forms. Moreover, quantitative differences were also
observed: the per, wbkA, and wa** mutants showed similar
proportions of the underacylated forms (bands c and d), but
band c was more prominent in the manBcore mutant (Fig. 5).
Virulence and stability in mice. The infection kinetics in the
spleens of BALB/c mice inoculated with the R mutants and B.
abortus RB51 are presented in Fig. 6. Although all strains
showed similar levels of splenic infection at day 5 (mean values
were all within 1 log), differences became apparent after the
day 8. At day 16, RB51 and wa** mutant produced similar
levels of splenic infection that were lower (P  0.0001) than
those of the other three R mutants. At day 21, the splenic
infection in mice inoculated with strain RB51 was lower (P 
0.05) than that of mice inoculated with wa**, and the latter
value was lower than in animals inoculated with the manBcore
and per mutants (P  0.0005). At this time, wbkA mutant
produced a level of infection higher than that of per or man-
Bcore mutant (P  0.05), and this difference also existed at the
end of the experiment (at day 35, RB51 and wa** mutant were
below the threshold detection level). In keeping with these
results, the RT50 calculated for RB51 and wa** mutant was
3.87 weeks, about half of the 7.85 weeks calculated for the per,
wbkA, and manBcore mutants. The RT50 of B. abortus 2308 Nal
r
(parental strain), calculated in an independent experiment,
was 	15 weeks. All of the spleen isolates showed the same
mini-Tn5 location and R phenotype as the inoculum.
Serological response in mice. In contrast to B. abortus 2308,
neither the transposon R mutants nor RB51 elicited antibodies
reacting with NH (Fig. 7, upper panel). At the end of the
experiment, all mutants induced IgG to the R-LPS of an in-
tensity comparable to that induced by B. ovis PA (Fig. 7,
middle panel). A more intense response was detected when the
sera were tested with R-LPS-Omp complexes (Fig. 7, lower
panel), and the difference with the results obtained with the
R-LPS was taken as demonstrative of an intense response to
group 3 Omps.
Protection in mice. Table 1 shows the results of experiments
in which mice vaccinated with the R mutants, RB51, or S19
were challenged with B. abortus 2308. Mutants affected in the
core (wa** and manBcore), as well as RB51, failed to protect
mice. The protection conferred by the wbk mutants (wbkA and
per) and S19 was statistically significant and different from that
obtained with RB51. S19 was the most effective of the three
vaccines. Since antibodies to Brucella O-polysaccharide are
protective in mice (37, 46, 54), a control experiment was per-
formed to confirm that the sections deleted by the mutation
contributed to this difference. To this end, groups of mice were
FIG. 4. SDS-PAGE (A) and Western blot analysis (B to F) of the LPS of strain 2308 Nalr (1) and the per (2), wbkA (3), wa*** (4), and manBcore
(5) mutants. The antibodies used were those in polyclonal sera to O-polysaccharide (B) and to the per (C) and manBcore (D) mutants or MAbs
to outer core (Baro-1 [E]) and inner core (Baro-2 [F]). Lanes Ra and Rd of panel A contained the LPS of serovar Minnesota Ra and Rd mutants.
FIG. 5. HPTLC analysis of lipid A heterogeneity of the LPS of B.
abortus 2308 Nalr (1) and of the per (2), wbkA (3), wa** (4), and
manBcore (5) mutants. Lane Ec contained lipid A of E. coli ATCC
35218. hexa, Hexa-acylated; penta, pentra-acylated; tetra, tetra-acy-
lated.
FIG. 6. Infection kinetics in the spleens of BALB/c mice inoculated
with the mini-Tn5 R B. abortus mutants and B. abortus RB51 (vertical
bars represent the SDs). Symbols: E, wbkA; ƒ, per; 1, manBcore; ,
wa**; Œ, RB51.
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vaccinated with S-LPS, PS, or S19 and challenged with B.
abortus 2308 (Table 2). PS did not protect mice, and a signif-
icant protection was obtained in mice vaccinated with S-LPS.
Noteworthy, the differences between the protection afforded
by S-LPS or S19 were not statistically significant.
The protection against B. ovis PA was also assessed (Table
3). Again, the mutants affected in the LPS core failed to afford
protection. The per and wbkA mutants and vaccines S19 and
RB51 afforded significant protection, with no statistically sig-
nificant differences among them. However, all mice vaccinated
with wbkA had cleared the infection, whereas three of the five
mice vaccinated with per mutant, RB51, or S19 remained in-
fected at termination.
DISCUSSION
The analysis of the LPSs of mutants in genes per and wbkA
confirm their involvement in the synthesis of Brucella O-poly-
saccharide (27, 28). Consistent with this, the epitopic structure
of the core of both mutants was unaltered. This does not
necessarily mean that the LPS of both mutants is identical
because, although the per mutant cannot synthesize the O
sugar, the wbkA mutant could incorporate a few perosamine
units to the LPS since several wbk glycosyltransferases (Fig. 2)
are likely to take part in O-polysaccharide biosynthesis. It was
also shown that genes wa** and manBcore are involved in the
biosynthesis of the B. abortus LPS core. This core is reported to
contain between 8 and 11 sugar residues, including Kdo, man-
nose, glucose, and glucosamine (21, 71). Phylogenetic and
sugar analyses strongly suggest that B. abortus LPS core is very
close to that of Ochrobactrum intermedium (71), with the con-
spicuous absence of galacturonic acid in the former. The par-
tial structure of the O. intermedium core and its lipid A disac-
charide has been elucidated for strain LMG3301 (72) and is
shown in Fig. 8, in which the O-polysaccharide is linked to
glucosamine through intermediate and unknown sugar(s), in-
cluding quinovosamine. In this structure, the absence of man-
nose should generate a deep R-LPS, with poor reactivity with
Baro-1-type MAbs, a Kdo content higher than those of mutant
LPSs with complete core or keeping the outer part of it, and a
marked electrophoretic mobility in SDS-PAGE. These fea-
tures are displayed by the LPS of the manBcore mutant and,
indeed, this reinforces the hypothesis that the B. abortus and O.
intermedium LPS cores are similar. Mannose linked to the first
Kdo is also found in the core of other Brucella phylogenetic
relatives (36). All of this evidence shows that the designation
manBcore is appropriate and that an effect on O-polysaccharide
(mannose is a perosamine precursor) synthesis is unlikely.
Such an effect was suggested before the complete wbk region
was available (2) but a search in the complete genomic se-
quence of B. melitensis 16M (17) and B. suis 1330 (50) and the
analysis of some of the corresponding mutants (J. J. Letesson,
unpublished data; D. Gonza´lez, D. Monreal, I. Lo´pez-Gon˜i,
and I. Moriyo´n, unpublished results) shows that several LPS
genes flank the seven genes (the wbkA-wbkC stretch) first
described in the region (27). These genes include manA,
manB, and manC (Fig. 2), and their position strongly suggests
that they act coordinately with gmd and per and independently
of other mannose genes. The location of manAcore-manBcore in
chromosome II (wbk is in chromosome I) also supports this
hypothesis because, on the bases of the GC content (ca. 48%
for wbk [including manA, manB, and manC] and 58% for the
Brucella genome), it is postulated that wbk was acquired hor-
izontally (14). It is evident that this means that independent
genes for core synthesis preexisted incorporation of wbk. In
fact, the %GC content of the manAcore-manBcore is close to
58%, indicating a long common evolution with non-LPS genes.
Not surprisingly, manAcore-manBcore highly homologous genes
are present in at least Mesorhizobium loti (66) and also in
Rhizobium sp. strain NGR234 where, as in B. melitensis and B.
suis (Fig. 2), they are flanked by a lysR homologue (22). The
manA, manB, and manC arrangement seems rare: it is not
found in the genomes of Brucella phylogenetic relatives (24, 29,
40, 49, 74), and manA is not present in the other wb regions
sequenced thus far that contain per and gmd (6, 35, 49, 51, 65),
including that of Y. enterocolitica O:9 (42), which, like B. abor-
tus, carries 
(1-2)-linked N-formyl perosamine O-polysaccha-
FIG. 7. Antibody response to surface antigens in mice inoculated
with mini-Tn5 R B. abortus mutants and B. abortus RB51. Horizontal
dashed lines mark the antibody levels in the blood of control mice 15
days after infection with either B. abortus 2308 or B. ovis PA. Day 0
values are from noninoculated mice. Symbols: E, wbkA; ƒ, per; 1,
manBcore; , wa**; Œ, RB51.
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rides (11). With regard to the wa** mutant and confirming the
role of this gene in LPS core biosynthesis, we found that the
mutation is complemented in the corresponding B. melitensis
16M mutant by a pBBR1MCS-4-wa** construct (Gonza´lez et
al., unpublished). In the wa** mutant LPS, the deficient inner
core epitope contrasts with the apparently intact outer core
epitope. It has to be noted that these are overlapping epitopes
(58), and this is one of the reasons that may account for the
partial reactivities observed with whole bacteria where the core
epitope deficiency was less noticeable than in Western blots.
The inner epitope encompasses the two Kdos plus some un-
known sugars linked to them (58), perhaps in a branch like that
carrying glucose and galacturonic acid in the O. intermedium
LPS core. If so, the absence of a sugar in such a position could
result in an inner core deficiency not affecting the outer core.
Structural studies are under way to elucidate this and other
aspects of the Brucella LPS core.
The SDS-PAGE and HPTLC analyses showed some heter-
ogeneity in the R-LPSs of the mutants. Heterogeneity has been
observed before by SDS-PAGE in the R-LPS of the B. abortus
45/20 (21) and B. abortus RA1 (a wboA Tn5 R mutant) (45).
Heterogeneity can result from both oligosaccharide or lipid A
differences, and we found that the mutations in the O-polysac-
charide and core genes had a pleiotropic effect on lipid A
manifested as a comparative underacylation. Underacylated
lipid A forms are preferentially observed in the short O-chain
and R LPSs (41), and this probably reflects the structural
adaptation of a membrane molecule that, when devoid of a
large portion of its hydrophilic moiety, does not need the
firmest possible hydrophobic anchorage. This explanation pos-
sibly applies to the lipid A of the Brucella R mutants. Besides,
since lipid A acylation modulates the LPS interaction with the
innate immune system (for a recent review, see reference 18),
it is conceivable that these variations in the lipid A of Brucella
R mutants could relate to their attenuation. So far, attenuation
of the R B. abortus and B. melitensis mutants has been ascribed
to the increase in both the antibody-independent complement
activation (2, 16, 19) and the sensitivity to polycationic bacte-
ricidal peptides (2, 44, 57). Moreover, since these bacteria are
intracellular parasites able to alter the normal intracellular
trafficking (52), other factors related to the interplay of R
mutant and host cells must be important; the anomalous lipid
A acylation and OM topology could be among them.
In spontaneous Brucella R mutants, B. ovis, and B. canis,
Omps are more readily accessible to antibodies than in S bru-
cellae, and this has been logically attributed to the absence of
the O-polysaccharide (8, 13, 56). Our results confirm this and
also show that a truncated LPS core results in a further in-
crease in the reactivity of antibodies to Omps and lipid A
disaccharide. This suggests a steric hindrance by the complete
core but an upset quantitative distribution is also possible for
some Omps, as suggested by the MAb reactivity with Omp16
and Omp19 in the manBcore mutant. At least for Omp3a (for-
merly Omp25), the insertion and folding of the protein seems
normal, as judged by the unaltered reactivities with MAbs to
conformational and linear epitopes. The Omp and LPS
epitope mapping was complemented by the analysis of phage
and polymyxin B sensitivity. The receptors for the brucellaph-
ages are not known. With regard to the R/C phage, the
manBcore mutant was comparatively resistant and, although it
is possible that its markedly altered Omp topology affects
phage binding, this suggests that the missing outer core section
is part of the receptor. Also intriguing is the unexpected in-
crease in polymyxin B resistance of the manBcore mutant be-
cause the two Kdo residues and the lipid A phosphates, which
are typical polymyxin B targets (70), were more accessible in
this mutant. It may be that the missing outer core section
TABLE 1. Protection of BALB/c mice against B. abortus 2308 by
vaccination with B. abortus R mutants, B. abortus RB51, and
B. abortus S19
Vaccine Mean log10 CFU in thespleen  SD Protection (U)
a
S19 strain 1.92  0.65b,c 3.59
RB51 strain 4.87  0.19d,e 0.64
per mutant 3.44  1.37b,f,g 2.07
wbkA mutant 3.27  2.02b,f,g 2.24
wa** mutant 5.24  0.17d,e,h 0.27
manBcore mutant 5.43  0.26
d,e,h 0.08
PBS 5.51  0.12e,h
a That is, the average of the log10 CFU in the spleens of PBS-inoculated mice
minus the average of the log10 CFU in the spleens of vaccinated mice.
b P  0.001 in comparison with PBS-treated mice.
c P  0.01 in comparison with RB51-inoculated mice.
d Not significant in comparison with PBS-treated mice.
e P  0.0001 in comparison with S19-inoculated mice.
f P  0.05 in comparison with S19-inoculated mice.
g P  0.05 in comparison with RB51-inoculated mice.
h not significant in comparison with RB51-inoculated mice.
TABLE 2. Protection of BALB/c mice against B. abortus 2308 by
vaccination with PS and S-LPS
Vaccine Mean log10 CFU in thespleen  SD Protection (U)
a
S19 strain 2.70  0.69e 3.4
S-LPS 3.36  1.14b,c 2.74
PS 5.31  0.99d 0.79
PBS 6.10  0.28
a That is, the average of the log10 CFU in the spleens of PBS-inoculated mice
minus the average of the log10 CFU in the spleens of vaccinated mice.
b P  0.005 in comparison with PBS-treated mice.
c Not significant in comparison with S19-inoculated mice.
d Not significant in comparison with PBS-treated mice.
e P  0.0001 in comparison with PBS-treated mice.
TABLE 3. Protection of BALB/c mice against B. ovis PA by
vaccination with B. abortus R mutants, B. abortus RB51,
and B. abortus S19
Vaccine Mean log10 CFU in thespleen  SD Protection (U)
a
S19 strain 2.09  1.83b,c 3.12
RB51 strain 2.10  2.29b,c 3.11
per mutant 2.35  2.51b,c 2.86
wbkA mutant 0.61  0.07d 4.6
wa** mutant 4.07  2.15e 1.14
manBcore mutant 5.66  0.32
e 0
PBS 5.21  0.52
a That is, the average of the log10 CFU in the spleens of PBS-inoculated mice
minus the average of the log10 CFU in the spleens of vaccinated mice.
b P  0.01 in comparison with PBS-treated mice.
c Not significant in comparison with PBS-treated mice.
d P  0.001 in comparison with PBS-treated mice.
e Not significant in comparison with PBS-treated mice.
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contains an acidic sugar, as happens in some Rhizobium spp.
(36). However, this is unlikely because sugar analyses show no
acidic sugars other than Kdo in B. abortus LPS (see above). A
possibility is that the “self-promoted uptake” mechanism by
which this antibiotic penetrates to cause cell death (70) is
hampered in the manBcore mutant, perhaps in relation to the
altered OM topology. Tibor et al. (67) have recently shown
that knocking out the omp19 gene, but not the omp10 gene,
increases the sensitivity to polymyxin, and this finding suggests
a link with an altered topology in this group of lipoproteins.
Confirming the work of Allen et al. (2), not all R mutants
were equally attenuated in mice. However, we found that the
deepest R manBcore mutant persisted in spleens for a longer
time than the wa** mutant, suggesting an important role for
the inner core sugars. This is not contradicted by the observa-
tion that the persistence of the wa** was similar to that of
RB51. Although this last strain carries a IS711 in wboA (equiv-
alent to BMEI 0998 or BR0982) (45) and may thus have a
complete core, complementation with wboA does not restore
S-LPS synthesis in RB51 (45). This demonstrates additional
and unknown LPS defects in RB51 and, consistent with this,
the Tn5 wboA mutant B. abortus RA1 is less attenuated than
RB51 in mice (45). The kinetics of infection and RT50 of RB51
reported here are similar to those of previous works (38, 61, 64,
73).
All of the studies comparing the efficacy of R and S vaccines
in mice have shown that, despite differences in dose, S vaccines
perform better against virulent S Brucella spp. (33, 64, 73).
Indeed, S vaccines elicit antibodies to the S-LPS and, whereas
the role of cellular immunity is clear, that of anti-S-LPS anti-
bodies against Brucella infection in natural hosts has been a
matter of controversy. In mice, however, it is clear that anti-
S-LPS antibodies are by themselves protective (37, 46, 54).
Thus, it is not known to what extent the S versus R vaccine
comparisons in mice are biased by the antibodies to O-poly-
saccharide. Our own results suggest that this effect must be
very intense because vaccination with S-LPS, which does not
induce significant cellular immunity (39), generated a protec-
tion against B. abortus not significantly different from that
obtained with S19. On the other hand, contrary to some re-
ports (12), the highly purified PS fraction did not induce im-
munity in mice. It seems, therefore, that it is currently difficult
to extrapolate results in the mouse model to the natural hosts
when S and R vaccines are compared, but this is not necessarily
true of R versus R comparisons.
There are few comparative studies on Brucella R vaccines
and none on the vaccine properties of R Brucella strains car-
rying progressive LPS defects. Winter et al. (73) tested B.
melitensis VTRM1 and B. suis VTRS1 (both are wboA mu-
tants) as vaccines against homologous and heterologous chal-
lenges in mice. These authors consistently found that both
mutants provided a better protection than RB51. Moreover,
we found that the two mutants carrying LPSs with no detect-
able core defects were better vaccines in mice than the two
mutants with core defects, no matter whether the animals were
challenged with virulent S or R brucellae and with no corre-
lation with the kinetics of multiplication in the spleen or, at
least in B. abortus, the antibody response to surface antigens.
These results have several implications. First, it is considered
that persistence is an advantage in a Brucella live vaccine be-
cause it should lead to a better cellular immunity (73). In part,
this is confirmed here for B. abortus because the vaccines with
shorter RT50 (wa** and RB51) failed to induce protection
against this species. However, persistence does not seem an
absolute criterion because the manBcore mutant, although
showing an RT50 similar to that of the per or wbkA mutants,
failed to induce protective immunity. It has been shown that
antibodies to Omps and, more important, to the R-LPS afford
protection against B. ovis in mice (9, 38). Thus, it can be
hypothesized that the outer core epitope is important in elic-
iting protection against B. ovis and, if so, the failure of the
manBcore mutant can be explained. However, the same expla-
nation is unlikely to account for the results with B. abortus
since anti-R-LPS antibodies bind poorly or not at all to S B.
abortus cells (the present study and reference 8). Finally, it can
be concluded that, at least in the mouse model, an intact core
is necessary for a Brucella R vaccine to be as effective as
possible. LPS structural studies and an analysis of the interac-
tion of R mutants and host professional and nonprofessional
phagocytes and their induction of cellular immunity could help
to clarify the basis of the differences between the core mutants
and also possible differences between the per and wbkA mu-
tants.
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FIG. 8. Partial structure of O. intermedium strain LMG3301 core and its lipid A disaccharide.
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